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Plasmodium vivax resistance to chloroquine (CQ) is currently reported in almost all countries where P. vivax is endemic. In
Vietnam, despite a first report on P. vivax resistance to chloroquine published in the early 2000s, P. vivax was still considered
sensitive to CQ. BetweenMay 2009 and December 2011, a 2-year cohort study was conducted in central Vietnam to assess the
recommended radical cure regimen based on a 10-day course of primaquine (0.5 mg/kg/day) together with 3 days of CQ (25 mg/
kg). Here we report the results of the first 28-day follow-up estimating the cumulative risk of P. vivax recurrences together with
the corresponding CQ blood concentrations, among other endpoints. Out of 260 recruited P. vivax patients, 240 completed
treatment and were followed up to day 28 according to theWHO guidelines. Eight patients (3.45%) had a recurrent P. vivax in-
fection, at day 14 (n 2), day 21 (n 1), and day 28 (n 5). Chloroquine blood concentrations, available for 3/8 recurrent infec-
tions (days 14, 21, and 28), were above theMIC (>100 ng/ml whole blood) in all of these cases. Fever and parasitemia (both sex-
ual and asexual stages) were cleared by day 3. Anemia was common at day 0 (35.8%), especially in children under 10 years (50%),
and hemoglobin (Hb) recovery at day 28 was substantial among anemic patients (median change from day 0 to 28,1.7 g/dl;
interquartile range [IQR],0.7 to3.2). This report, based on CQ blood levels measured at the time of recurrences, confirms
for the first time P. vivax CQ resistance in central Vietnam and calls for further studies using standardized protocols for accu-
rately monitoring the extent and evolution of P. vivax resistance to chloroquine in Vietnam. These results, together with the
mounting evidence of artemisinin resistance in central Vietnam, further highlight the increasing threat of antimalarial drug re-
sistance to malaria elimination in Vietnam.
Plasmodium vivax is the most widely distributed malaria para-site species; an estimated 2.85 billion people were at risk of
infection in 2009, the vastmajority (2.59 billion [91.0%]) living in
central and southeast Asia (1). Moreover, since malaria elimina-
tion has been on the global health agenda (2), the public health
importance of vivax malaria has been increasingly reassessed,
since it is more difficult to control than Plasmodium falciparum
malaria, and severe clinical syndromes as well as new foci of chlo-
roquine resistance are increasingly reported (3–5). Chloroquine
(CQ) is the first-line treatment for P. vivax in most countries
where it is endemic. P. vivax resistance to CQwas first reported in
1989 from Papua New Guinea (PNG) (6), rapidly followed by
reports from Indonesia in 1991 (7, 8), Myanmar in 1993 and 1995
(9, 10), India in 1995 (11, 12),Malaysian Borneo in 1996 (13), and
several South American countries (Guyana, Brazil, and Colum-
bia) from 1996 onwards (14–16). In Vietnam, little evidence of P.
vivax susceptibility to CQ has been published so far; one study in
Binh Thuan province (southeastern coast region) in the early
2000s reported P. vivax resistance to chloroquine (17), while this
was absent in the neighboring Khanh Hoa province (18). The
National Malaria Control Program (NMCP) has been closely
monitoring antimalarial drug resistance,mainly focused on P. fal-
ciparum resistance (19–21), since 1995 in several sentinel sites
across the country. Since 2003, P. vivax susceptibility to CQ has
been assessed in six sentinel sites, and a rate of between 0 and 5.7%
of late parasitological failures has been reported (22).
Vietnam is currently engaged in malaria elimination (23, 24),
and the issue of drug resistance is a priority, as P. falciparum resis-
tance to artemisinins has been already reported in five (Tier I)
provinces of central Vietnam (25, 26). Moreover, the control of P.
vivax is another challenge, as this species is becoming increasingly
prevalent (27–30). The main difficulty in controlling vivax ma-
laria lies in the need to radically treat not only blood forms but also
the hepatic dormant forms (hypnozoites) that cause relapses for
months to years after the initial infection. The World Health Or-
ganization (WHO) currently recommends for radical cure a 3-day
course of CQ (total of 25 mg/kg) together with a 14-day course of
primaquine (PQ) (0.25 mg/kg/day), the recommended treatment
in Vietnam since 2009. Nevertheless, between 2007 and 2009, in-
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stead of the 14-day course, PQ was given for 10 days at a higher
dose (0.5 mg/kg/day) (31). The efficacy of such treatment on liver
stages was assessed by following up a cohort of treated P. vivax
patients in central Vietnam for 2 years. We report here the results
of the first 28-day follow-up done according to the WHO guide-
lines (32).
MATERIALS AND METHODS
Study site andparticipants.The studywas carried out betweenApril 2009
and December 2011 at the Tra Leng Commune Health Center (CHC),
located in a remote forested area in the southwestern part of Quang Nam
province, central Vietnam. A detailed description of the study area and
population has been reported elsewhere (33). The study was designed as a
28-day follow-up after treatment of Plasmodium vivax cases with CQ and
PQ (32). Male and female patients, aged between 3 and 60 years, present-
ing at the CHC (or identified through active case detection by the study
team) with suspected malaria were screened for eligibility. Inclusion cri-
teria were as follows: axillary temperature of 37.5°C and/or history of
fever in the previous 48 h, P. vivax monoinfection with asexual parasites
confirmed by light microscopy (LM), residency in the study area, and
written informed consent from all participants aged 18 years or older (or
from parents/guardians for minors). Patients were excluded if they pre-
sented general danger signs with severe or complicated malaria, had any
acute or chronic concomitant illness, or had already been treated with PQ
within the past 30 days. Pregnant or lactating women, patients with
known glucose-6-phosphate dehydrogenase (G6PD) deficiency (or his-
tory of “black urine” followingPQ treatment), or patientswith any history
of intolerance to the study drugs were excluded. According to the national
guidelines, patients were not tested for G6PDdeficiency prior to PQ treat-
ment. The prevalence of G6PD genetic polymorphism (Viangchanmuta-
tion) was estimated to be below 1.5% in bothmales and females (33), with
no difference between ethnic groups.
Procedures. Study drugs were provided by the national malaria con-
trol program and consisted of CQ tablets of 300 mg chloroquine base (lot
no. 08001CN; registration no. VNB-4144-05) and PQ tablets containing
15 mg primaquine base (lot no. 010109; registration no. VD-0877-06).
A general physical examination was performed at inclusion (day 0)
and daily during treatment (days 1 to 9); subsequently, patients were
examined weekly at days 14, 21, and 28 and during any unscheduled visit.
Patients were asked to return daily to the CHC for direct observed therapy
with CQ (25 mg base/kg) and PQ (0.5 mg/kg/day) during the first 3 days
(days 0 to 2) and thenwith PQ alone for the remaining 7 days (days 3 to 9).
More specifically, signs and symptoms of acute hemolysis (jaundice, black
urine, fatigue, tachycardia, shock, etc.) were systematically checked at
each visit by the study clinician; adverse drug reactions and concomitant
medications were recorded. Patients not attending scheduled visits were
visited at home. Any recurrent P. vivax or P. falciparum infection detected
by LM during the 28-day follow-up was treated with dihydroartemisinin-
piperaquine (DHA-PPQ) for 3 days following national guidelines.
Blood samples (finger prick) were collected at days 0, 1, 2, 3, 7, 14, 21,
and 28 for LM (blood films) and later molecular analysis (2 blood spots
dried on filter paper). Additional blood samples were taken at days 0, 14,
and 28 for hemoglobin (Hb) concentration; at day 7 and any day of re-
current P. vivax infection, 100 l of blood was taken on a separate filter
paper for later measurement of CQ blood level.
Thick and thin filmswere stainedwith 3%Giemsa solution for 45min;
parasite density was estimated by counting the number of parasites per
200 white blood cells (WBCs) and assuming 8,000 WBCs/l. A slide was
declared negative if no parasite was found after counting 1,000WBCs. All
slides were read independently by two expert technicians who in case of
discrepancy reread the slide until reaching agreement. A later and system-
atic quality control examination of all blood slides was done by a senior
technician at the central level (NIMPE, Hanoi); in case of disagreement, a
second senior technician would reread the slide until agreement was
reached. The hemoglobin concentration was measured with the
HemoCue Hb 301 device (HemoCue AB, Angelholm, Sweden) following
the manufacturer’s instructions (34). Filter paper blood samples (FPBS)
were dried outside direct sunlight, kept in individual sealed plastic bags,
and stored at20°C (NIMPE, Hanoi) until they were processed.
The concentrations of CQ and desethylchloroquine (DEC) in dried
blood filter paper samples were determined using a validated high-pres-
sure liquid chromatography (HPLC)methodwith a fluorescence detector
at excitation and emission wavelengths of 250 and 400 nm, respectively, a
modification of the previous published method (35). Following mincing
of the filter paper (Whatman grade 3), extraction was performed using 3
ml of 25% ammonia and 3 ml of ethyl acetate-hexane (1:9). The solution
was vortexed for 30 s and centrifuged to separate the organic phase, which
was then transferred to another tube and evaporated to dryness. The sam-
ple was reconstituted with HPLC mobile phase, and 20 l was injected
into the HPLC system (Waters, USA).We used an X-Bridge Phenyl 5-m
(4.6- by 150-mm) column as the stationary phase. Themobile phase used
was diethylamine (0.05%)-acetonitrile (55:45), pumped isocratically at
flow rate of 1.0 ml/min and temperature of 30°C. Pyrimethamine was
used as an internal standard.
Outcomes. Efficacy outcomes were classified into early treatment fail-
ure (ETF), late clinical failure (LCF), late parasitological failure (LPF), or
adequate clinical and parasitological response (ACPR), following the
WHO criteria (32). For all efficacy outcomes, no distinction was made
between relapse, recrudescence, and reinfection, and any newmicroscop-
ically detectedP. vivax infection after initial parasite clearancewas defined
as “P. vivax recurrence.” The primary endpoints were the proportion of
patients with ACPR by day 28 and the parasite clearance time (PCT).
Secondary endpoints included fever and gametocyte clearance times, the
proportion of confirmedCQ-resistant P. vivax recurrences (CQplusDEC
concentration of100ng/ml), andhematological changes betweendays 0
and 28.
Data analysis. The sample size was calculated on the basis of retro-
spective data (2003 to 2007) reporting LPF ranging from 0% to 5.7%
among P. vivax patients treated with CQ (22). Assuming a minimum
treatment failure rate of 5% and a loss to follow-up of 10%, a sample size
of 204 P. vivax patients would be needed for estimation with a 3% preci-
sion and at 5% significance level (“CSample” command/Epi Info 6). The
sample size was further increased to comply with the requirements of the
cohort evaluation, details of which will be published separately. Data were
double entered and cleaned using Epidata version 3.1. The data set was
analyzed using STATA version 11 (Stata Corp., College Station, TX). The
survey design (survey data set) was taken into account using the svy com-
mand in STATA, with villages as strata and household as sampling unit.
Descriptive statistics were used to compute baseline sociodemographic
characteristics. Ownership of livestock (pigs, buffaloes, and cows) was
used as a proxy for the economic status of the household, using a princi-
pal-component analysis (33). The PCTwas estimated using the daily pro-
portion of patients still parasitemic from day 0 until the day of complete
parasite clearance. The proportion of recurrence-free patients by day 28
was assessed by Kaplan-Meier survival analysis. Patients were censored on
the day they had last been seen in follow-up. Fever clearance time was
estimated by determining the proportion of febrile patients during fol-
low-up among febrile patients at day 0. Similarly, gametocyte clearance
was expressed as the proportion of patients with gametocytes during fol-
low-up among gametocyte-positive patients at day 0. Hematological re-
covery was estimated by computing the median Hb concentration at days
0, 14, and 28 as well as the median of individual Hb differences between
day 0 and day 28. Anemiawas defined as anHb concentration of11 g/dl,
for both sexes and all ages (36). TheWilcoxon rank sum test and sign rank
test were applied as required to compare Hb medians. A survey logistic
regression (“svy” command in STATA) was used to carry out a multivar-
iate adjusted analysis for the risk of anemia before and after treatment
(adjusting for all potential confounders, such as sex, age, baseline para-
sitemia, splenomegaly, and ethnicity). Similarly, survey logistic regression
was also used to assess if baseline parasite density (day 0) or age was
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independently associated with parasite clearance at day 2. A multivariate
linear regression model was used to determine the independent effect of
the baselineHb values (day 0Hb0) on the relativeHb changes at day 14.
Potential risk factors (age, ethnicity, etc.) with a P value of 0.05 in the
univariate analysis were included in themultivariatemodel and retained if
the P value was0.05. Interactions were systematically checked for up to
order two. The 5% cutoff was defined as a significant P value for all sta-
tistical tests.
Ethical clearance. Ethical clearance was obtained from both the Eth-
ical Committee of the NIMPE in Hanoi and that of the University of
Antwerp. The fundamental principles of ethics in research on human
participantswere upheld throughout the project. The study objectives and
methods were explained to the people’s committee, the village’s leader,
and the local people. All study participants had given their informed con-
sent after the study objectives and procedures, as well as their right to
withdraw without prejudice for themselves or their families, were ex-
plained. Written informed consent was obtained from parents or guard-
ians of children below 18 years; children between the ages of 12 and 18
years were asked to provide a written assent.
RESULTS
Trial profile and baseline characteristics. Between April 2009
and December 2010, 260 P. vivax-infected patients were enrolled
and given the 10-day radical treatment of PQ (0.50 mg/kg/day)
associated with CQ for the first 3 days (total, 25 mg/kg); 240 pa-
tients (92.3%; 240/260) completed the treatment and were in-
cluded in the analysis, and 232 patients completed the 28-day
follow-up. All incomplete follow-ups were due to consent with-
drawal (Fig. 1) following prolonged absence, mainly because of
work requirement in forest fields. Patients were recruited in all
four study villages, and the vast majority (78.5%; 204/260) be-
longed to the M’nong group (Table 1). Males (61.1%; 159/260)
slightly outnumbered females, and almost half of the participants
(43.1%; 112/260) were children aged 3 to 9 years. The majority of
participants had no bed net at home (70.8%; 184/260) and very
low socioeconomic status, and all adults were farmers.
More than half of the study patients (59.2%; 154/260) had
measurable fever at enrollment; headache (36.1%; 94/260) and
fatigue (33.1%; 86/260) were the most common symptoms, and
about 6% (16/260) had an enlarged spleen. The mean parasite
density at enrollment was 2,754.1/l (geometric mean [GM]),
and gametocytes were found in most of the patients (86.1%; 224/
260), though at much lower densities (GM 387.7/l). The me-
dian hemoglobin concentration at enrollment was 11.7 g/dl, and
more than one-third of the patients (35.8%; 93/260) were anemic
(Hb,11g/dl). The treatment was well tolerated, no clinical sign
or symptoms of acute hemolysis were observed (despite the oc-
currence of transient acute hemolysis [see below]), and only few
patients (12.3%; 32/260) complained of nausea following PQ ad-
ministration, though none of them vomited their dose of CQ
or PQ.
Primary endpoints. No ETF was observed; there were eight
late treatment failures, i.e., 2 LPFs at day 14, 1 LCF at day 21, and
5 LPFs at day 28 (Table 2). The rate of ACPR at day 28 was 96.6%
(95% confidence interval [CI], 93.7 to 98.2). P. vivax recurrence
was not associated with delayed parasite clearance, as five of the
FIG 1 Study profile.
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eight patients with recurrence had cleared parasitemia before 24
h. The mean parasite density at day of recurrence was very low
(GM 41.1/l; interquartile range [IQR], 23.3 to 855.8).
At day 1, more than half of the patients (57.9%) were still
parasitemic, at day 2 only 7.1% were, and at day 3 none of them
had detectable parasitemia. Parasite clearance at day 2 was signif-
icantly associated with a higher asexual parasite density at day 0
(odds ratio [OR] 1.79; 95%CI, 1.14 to 2.82; P 0.012) but not
with age.
Secondary endpoints. All patients were afebrile and without
gametocytemia by day 3 (Table 2). Dried blood samples for mea-
suring CQ blood concentrations were available (at day 7 and the
day of recurrence) for 5 of the 8 patients with vivaxmalaria recur-
rence, and among these, three had interpretable results. The CQ
blood concentrations at day 7 ranged from 365.1 to 1,347.1 ng/ml,
confirming adequate drug absorption. The three CQ blood con-
centrations at time of recurrence were 114.7 ng/ml (day 14), 133.1
ng/ml (day 21), and 125.9 ng/ml (day 28); all of them were above
the 100-ng/ml threshold, confirming CQ resistance.
ThemedianHb value at day 0 among patients with ACPR (n
224) was 11.7 g/dl (IQR 10.5 to 13.1), and children were signif-
icantly more at risk of anemia (50.0%; 49/98) than older patients
TABLE 1 Baseline demographic, clinical, and parasitological characteristics at enrollment (n 260)
Parameter n % 95% CI
Village
1 101 38.85 34.83–43.02
2 64 24.62 21.25–28.33
3 39 15.0 12.84–17.45
4 56 21.54 17.63–26.04
Gender
Male 159 61.15 55.76–66.82
Female 101 38.85 33.72–44.24
Ethnic group
M’nong 204 78.46 73.96–82.37
Cadong 56 21.54 17.63–26.04
Age (yr)
3–9 112 43.08 37.45–48.89
10–19 71 27.31 21.84–33.55
20–29 44 16.92 12.75–22.11
30–60 33 12.69 9.36–17.0
Occupation
None (children6 yr) 70 26.92 22.02–32.47
Farmer 85 32.69 27.51–38.34
Pupil 105 40.38 34.34–46.74
Bed net in house
None 184 70.77 61.81–78.37
At least one 76 29.23 21.63–38.19
Economic statusa
Lowest 147 56.54 47.20–65.43
Low 26 10.0 5.70–16.96
Higher 87 33.46 25.18–42.9
Clinical symptoms (most frequently reported)
Fever (axillary temp37.5°C) 154 59.23 53.06–65.12
Headache 94 36,15 30.42–42.32
Fatigue 86 33.08 27.23–39.5
Dizziness 28 10.77 7.51–15.22
Nausea 32 12.31 8.83–16.90
Enlarged spleen 16 6,15 3.58–10.39
Laboratory data
Asexual parasites/l, GM (95% CI) 2754.07 (2271.87–3338.61)
Gametocytes/l, GM (95% CI) 387.72 (324.84–462.80)
Patients with gametocytes 224 86.15 81.37–89.86
Hemoglobin (g/dl), median (IQR) 11.7 (10.4–13.1)
Patients with anemia (Hb 11 g/dl) 93 35.77 29.8–42.21
a Score in tertiles defined as “high,” “medium,” and “low” economic status, following principal-component analysis (33).
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(23.0%; 29/126) even after adjusting for baseline parasitemia (ad-
justed OR [AOR] 3.60; 95%CI, 1.88 to 6.88; P 0.001). By day
28, themedianHb increased to 12.3 g/dl (IQR 11.3 to 13.4), and
themedian value of individual Hb changes between day 0 and day
28 was0.7 g/dl (IQR0.2 to1.6). Among anemic patients
at day 0 (n 78), themedianHbwas 9.9 g/dl (IQR 8.3 to 10.5),
and it significantly increased to 11.5 g/dl (IQR 10.8 to 12.1) by
day 28 (sign rank test, P 0.001), with a median change of1.7
g/dl (IQR  0.7 to 3.2) (Fig. 2A). This change was slightly
lower in children (median  1.5 g/dl; IQR, 0.7 to 2.5) than in
adults (median  1.9; IQR, 1.1 to 4.2) (Wilcoxon rank sum test,
P  0.08). After treatment, 24.5% (24/98) of children and 8.7%
(11/126) of adults were still anemic (AOR  3.5; 95% CI, 1.7 to
7.0; P  0.001). Patients who were still anemic by day 28 were
treated with hematinic drugs (ferrous sulfate and folic acid).
In order to better understand the relationship between Hb
changes, age and baseline Hb values (Hb0), we plotted the indi-
vidual changes at day 14 relative to day 0 (%) (Fig. 2B) as a func-
tion of Hb0 and carried out a multivariate linear regression anal-
ysis adjusting for the potential confounding effect of age. The final
model showed that relative Hb changes at day 14 were indepen-
dently (and negatively) associated with Hb0 (P 0.001) and that
age was not a confounder, since it was associated only with the
exposure and not with the outcome variable. Moreover, the
linear regression model showed that the effect of Hb0 on rela-
tive Hb changes at day 14 was significantly different between
anemic and nonanemic patients at day 0 (interaction term co-
efficient   5.99; P  0.001). Indeed, while in nonanemic
patients the Hb decreased by 6.5% for every increase in Hb0
unit (  6.45; P  0.001), in the anemic group, the Hb
increased by 10% for every decrease in Hb0 unit (  10.00;
P  0.001). Interestingly, 9 patients experienced more than a
25% reduction in Hb by day 14, ranging from 58.2%
to 32.8%, without any sign or symptom of hemolysis de-
tected during the 28-day follow-up. All but one of these pa-
tients had normal Hb values at day 0, and the majority (6/9) of
them had recovered a normal Hb value by day 28.
Similar results were found for the association betweenHb0 and
relative Hb changes by day 28, with a significant interaction (in-
teraction term P 0.001) and a slightly stronger effect ofHb0
among anemic patients (  14.00; P  0.001) and a smaller
effect (3.38%;P 0.001) in the nonanemic group (data not
shown).
DISCUSSION
This study confirms for the first time P. vivax CQ resistance in
Vietnam, as three patients with recurrent P. vivax infections were
found to have CQ blood concentrations above the MIC (100
ng/ml of whole blood). Suspected P. vivax resistance to chloro-
quine was observed in Binh Thuan province in southern Vietnam
in the late 1990s, with 16% treatment failure after a 3-day course of
CQ (25 mg/kg) (17), but could not be confirmed because CQ
blood concentrations were not available. Indeed, the latter is nec-
essary (37), as recurrent infections could be the consequence of
TABLE 2 Primary and secondary endpoints
Endpoint n (%) 95% CI
Primary (n 240)
Adequate clinical and parasitological response (KMa) 224 (96.55) 93.67–98.15
Cumulative incidence of treatment failures (KM) 8 (3.45) 1.85–6.33
Late clinical failure (day 21) 1
Late parasitological failure (n 7) at day:
14 2
28 5
Patients with asexual parasitemia at day:
1 139 (57.92) 51.44–64.13
2 17 (7.08) 4.39–11.23
3 0
Secondary
Fever clearance (n 139 100% at day 0) at day:
1 34 (24.46) 18.7–31.32
2 5 (3.59) 1.49–8.41
3 0
Gametocyte clearance (n 207 100% at day 0) at day:
1 83 (40.1) 33.96–46.56
2 11 (5.31) 3.0–9.23
3 0
CQ blood concn at day of failure 100 ng/ml at day: 3/3
14 (LPF) 114.66
21 (LCF) 133.09
28 (LPF) 125.87
Hemoglobin recovery, median individual Hb change from day 0–28, g/dl
(IQR) for patients:
All (n 224) 0.7 (0.2–1.6)
Anemic at day 0 (n 78) 1.7 (0.7–3.2)
Nonanemic at day 0 (n 146) 0.25 (0.4–1.0)
a KM, Kaplan-Meier estimate.
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inadequate drug concentration due to suboptimal drug quality
and dosage or low intestinal absorption rather thanCQ resistance.
For this study, these factors can be excluded, as the day 7 CQ
concentrations were within the optimal range, at least for the five
patients with available results at day 7.
Since the first reports from Papua New Guinea (PNG) in 1989
(6, 8, 38, 39), P. vivax resistance to chloroquine has rapidly
reached unacceptably high levels in Indonesia and PNG, prompt-
ing the WHO to recommend artemisinin-based combination
therapies for P. vivax (40). Moreover, a recent systematic review
showed that P. vivax resistance to chloroquine can be found in
most countries where vivax malaria is endemic, across continents
(41). The apparently low cumulative risk of recurrence by day 28
estimated in our study together with the absence of ETF suggest a
low grade of resistance compared to that in other Southeast Asian
countries, particularly Indonesia, where ETFs ranged from 6% to
24% and 28-day recurrence rates from 18% to 100% (41). Simi-
larly, the recurrence rate may be considered negligible compared
to that (16%) observed in BinhThuan province about 15 years ago
(17). Nevertheless, when considering that CQwas coadministered
with high-dose (0.5-mg/kg/day) PQ, which has also an effect on P.
vivax asexual blood stages (42, 43), the estimation of P. vivax re-
sistance to chloroquine provided here is probably much lower
than its true prevalence. Indeed, in Indonesia adding PQ to CQ
decreased the day 28 treatment failure from 78% to 15% (39).
Therefore, our seemingly low-grade resistance is the CQ failure
when combined with high-dose PQ, while the true failure related
to CQ resistance is probably higher, possibly up to 5-fold higher
FIG 2 (A) Median hemoglobin (Hb) concentration at days 0, 14, and 28 (n  224 patients with ACPR); (B) relative Hb change (between day 0 and day 14)
according to baselineHb values (cutoff for anemia, Hb concentration of11.0 g/dl) (n 240). RelativeHb change on day 14 (%) by linear regression: (i) anemia
group, coefficient   10.00; 95% CI, 12.81 to 7.19; P  0.001; (ii) nonanemia group,   6.46; 95% CI, 7.41 to 5.51; P  0.001. A significant
interaction was found between Hb change at day 14 and anemia status at day 0 (interaction term  5.99; 95% CI,8.87 to3.11; P 0.001).
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(39). Therefore, P. vivax resistance to chloroquine in Quang Nam
province is probably similar to that reported 15 years ago from
Binh Thuan province (17). As CQ (monotherapy) efficacy mea-
sured in 6 sentinel sites in central and southern Vietnam between
2006 and 2011 has been consistently at 100% (24), it is possible
that P. vivax resistance to chloroquine in Vietnam has not reached
the high levels observed in PNG and Indonesia. Indeed, despite
the lack of power, with sample sizes between 25 and 65 patients
(24), which are far below theminimumof 75 recommendedby the
WHO (32), it is unlikely that high-grade resistance would have
been missed. Therefore, P. vivax resistance to chloroquine was
present in central and southern Vietnam since at least the late
1990s, and unlike in PNG and Indonesia, it did not evolve to
high-grade levels. The most likely explanation for such a differ-
ence could be the much lower CQ pressure, as artemisinin deriv-
atives have been used since the early 1990s for the treatment of
multidrug-resistant P. falciparum.
When considering the timing of the observed recurrent infec-
tions, the two LPFs at day 14 are probably recrudescences, as P.
vivax infections recurring before day 16 are almost certainly due to
a recrudescence from the primary infection (37). Infections recur-
ring latermay be either recrudescences or relapses, with CQ-resis-
tant parasites if the CQ blood level is above the MICs (37). As this
is an area of extremely low transmission,more than one infectious
bite within 1 month is unlikely, though it cannot be excluded as
farmers often stay overnight in their forest fields, where they are at
higher risk of exposure to the main vector, Anopheles dirus (44,
45). Genotyping alone is usually of limited help to distinguish
between recrudescence and relapse/new infection, since relapses
can occur with either the same or different clones (46).
Vivax malaria-associated anemia was common, and hemato-
logical recovery at day 28 depended on baseline Hb. Indeed, the
more pronounced hematological recovery was observed among
patients who were anemic before treatment. This observation is
similar to a recent report from PNG (47). In addition, young chil-
drenwere at amuch higher risk of anemia than older patients, and
this risk remained high after treatment, illustrating the impor-
tance of an efficacious radical treatment for P. vivax in children
(48). The linear regression model showed that age was indirectly
associated with Hb changes only through its significant associa-
tion with Hb0. Moreover, in anemic patients, the lowest Hb0 val-
ues corresponded to the moremarked Hb increase during follow-
up; for the other patients, the higher the Hb0, the more marked
was the Hb decrease during follow-up. This inverse relation could
be partly explained by the increased hemolytic risk in older red
blood cells (49) and by the suppressive activity of hemozoin (di-
gested Hb) on erythropoiesis (50). It is possible that anemic pa-
tients were infected for longer periods and at day 0 had already
reached their lowest Hb value. This would have resulted in amore
robust bone marrow response than in nonanemic, recently in-
fected patients (47). Transient asymptomatic Hb reductions
(50%) after PQ treatment, as either radical cure or single game-
tocytocidal dose, have been observed among G6PD-deficient and
nondeficient African children (51–53).
A quick post hoc genotyping (54) was carried out to screen for
the four most commonly reported G6PD mutations in Vietnam
(Vieng Chang, Canton, Union, and Kaiping) among the 9 patients
who experienced a 25% reduction in Hb by day 14 (together
with 9 randomly selected control patients [having no change in
Hb]). Only one patient was found positive for the Vieng Chan
mutation, i.e., a 26-year-oldmale of Cadong ethnicity with a tran-
sient Hb decrease of 52.9% by day 14 (Hb0 14.0 g/dl) followed
by a full recovery at day 28 (Hb28 13.6 g/dl). It is not possible to
exclude, among these 9 patients, the presence of other G6PD vari-
ants (i.e., Vietnam I, Vietnam II, Gaohe Gaozhou, Coimbra, etc.)
also reported in different ethnic groups from central Vietnam (55,
56). This will be further investigated by carrying out an in-depth
analysis of the G6PD genetic polymorphism in all 240 study pa-
tients in relation to their Hb changes. Moreover, the observed
transient but potentially life-threatening hemolysis (50% Hb
change at day 14) questions the national policy, which currently
does not recommendG6PD testing prior to radical PQ treatment.
To better estimate the risk of hemolysis linked to PQ use, there is
the urgent need of determining the prevalence of the G6PD-defi-
cient phenotype together with the G6PD genetic polymorphisms
among different ethnic minorities living in areas of residual ma-
laria endemicity.
The main limitation of our study is the concomitant use of PQ
and CQ, which most likely resulted in a substantial underestima-
tion of the true CQ-related cumulative risk of recurrence by day
28. As per WHO recommendations (32), P. vivax resistance to
chloroquine can be accurately estimated only by standard 28-day
in vivo studies with CQ monotherapy, with PQ being withheld
until day 28. Strictly speaking, resistance could not be confirmed
in all eight vivax malaria recurrences, as CQ blood levels results
were available for only three patients. However, given the phar-
macokinetics of CQ (37), it is likely that the other patients also had
adequate CQ blood levels. In addition, the concomitant adminis-
tration of PQ and its synergistic effect on asexual blood stages
could also explain why no association was found between the PCT
and the risk of recurrence, unlike that reported in a recent meta-
analysis by Price and colleagues (41). For all these reasons, a new
study has been initiated using CQmonotherapy to accurately de-
termine its in vivo and in vitro efficacy for treating P. vivax infec-
tions.
Another limitation of our study is the 24-h sampling schedule,
which was not optimal for an accurate determination of the PCT.
For future studies, 8- to 12-h sampling and a baseline parasite
density of at least 250/l are needed to accurately determine par-
asite clearance (32, 57).
Conclusion. In conclusion, this is the first confirmed evidence
of P. vivax resistance to chloroquine in central Vietnam, an area
where we recently reported P. falciparum resistance to artemis-
inins (25). P. vivax resistance to chloroquine should continue to
be monitored in different sentinel sites of central Vietnam, using
standardized and sufficiently powered in vivo protocols with CQ
monotherapy andwith PQ therapy delayed to day 28. Vietnamhas
committed to malaria elimination by 2030, and within this con-
text, antimalarial drug resistance, not onlyP. falciparum resistance
to arteminins but also P. vivax resistance to CQ, is as a major
threat. New treatment guidelines based on short and highly effec-
tive drug regimens as well as regional and Plasmodium genus-wide
integrated strategies for the containment of antimalarial drug re-
sistance in the Greater Mekong Subregion need to be urgently
developed.
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